NASDAQ:KYMR

Kymera Therapeutics Stock Insider Trading

etoro logo Buy KYMR
*Your capital is at risk
$103.40
-3.61 (-3.37%)
At Close: Jul 31, 2026

Kymera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -98.93. In total, the insiders bought 496.76K and sold 2.74M KYMR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-98.93
Buy 496.76K shares
Sell 2.74M shares
10% Buy Activity
Negligible or No Correlation
Sell Signal High Confidence
Jun 26, 2026

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -98.93.
  • Confidence increased due to high data reliability score of 100.
  • Supported by overwhelming sell-side pressure (10% buys).

Historical Insider Trades

Date Type Person Role Amount
Jul 27, 2026
Buy
Common Stock
J-Other
Rooney Terence
Insider
Other 0
Value: $0
Jul 27, 2026
Buy
Stock Option (Right to Buy)
A-Award
Rooney Terence
Chief Medical Officer
Officer 76 000
Value: $8.36M
Jul 27, 2026
Buy
Common Stock
A-Award
Rooney Terence
Chief Medical Officer
Officer 38 000
Value: $4.18M
Jul 07, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Mainolfi Nello
Chief Executive Officer
CEO / President 4 441
Value: $9K
Jul 07, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Mainolfi Nello
Chief Executive Officer
CEO / President 45 559
Value: $94.8K
Jul 07, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 50 000
Value: $5.95M
Jul 07, 2026
Buy
Common Stock
M-Exempt
Mainolfi Nello
Chief Executive Officer
CEO / President 50 000
Value: $104.0K
Jul 01, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 1 883
Value: $212.4K
Jul 01, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 6 626
Value: $755.2K
Jul 01, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 24 105
Value: $2.77M
Jul 01, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Mainolfi Nello
Chief Executive Officer
CEO / President 80 000
Value: $166.4K
Jul 01, 2026
Buy
Common Stock
M-Exempt
Mainolfi Nello
Chief Executive Officer
CEO / President 80 000
Value: $166.4K
Jul 01, 2026
Sell
Common Stock
S-Sale
Goodman Noah
Chief Business Officer
Officer 3 389
Value: $387.3K
Jul 01, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 3 336
Value: $388.8K
Jul 01, 2026
Sell
Common Stock
S-Sale
Mainolfi Nello
Chief Executive Officer
CEO / President 44 050
Value: $5.10M
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 6 153
Value: $719.9K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 7 971
Value: $923.2K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 51 375
Value: $5.90M
Jun 30, 2026
Buy
Stock Option (Right to Buy)
M-Exempt
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 61 378
Value: $327.1K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 4 110
Value: $469.3K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 1 100
Value: $124.1K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 1 700
Value: $189.7K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 1 500
Value: $165.8K
Jun 30, 2026
Buy
Common Stock
M-Exempt
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 61 378
Value: $327.1K
Jun 30, 2026
Sell
Common Stock
S-Sale
Jacobs Bruce N.
Chief Financial Officer
C-Suite Officer 3 200
Value: $376.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT KYMERA THERAPEUTICS INC.
Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...
GOLDEN STAR
Ticker Change Signal Date
FOX
$50.81
2.22% Jul 27
UNFI
$49.05
3.63% Jul 27
BIIB
$202.19
0.376% Jul 24
TSCO
$30.32
1.48% Jul 23
S
SW
$43.71
5.17% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE